Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation of [14C]Iruplinalkib in Healthy Male Volunteers
NCT05716126Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iruplinalkib in non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Primary endpoints: Metabolic profiling for iruplinalkib(WX-0593) in plasma, Metabolic profiling for iruplinalkib(WX-0593) in urine and 3 more. Started Apr 2020; status: completed.
02
Drugs
iruplinalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05716126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716126.